New clinical trial for patients with asbestos-associated lung cancer

The standard treatment for pleural mesothelioma is currently surgery to remove the patient's lung - a potentially debilitating consequence.

"Current surgical and chemotherapy treatments of patients with malignant pleural mesothelioma are unsatisfactory, and have not been shown to significantly prolong survival. In this study, we will investigate whether a combination of chemotherapy and radiation targeted directly at the lung's lining can improve outcomes while avoiding surgery," says Dr. Robert Taub, the study's principal investigator, director of the Mesothelioma Center at NewYork-Presbyterian/Columbia and professor of clinical medicine at Columbia University College of Physicians and Surgeons. "In addition, this approach has shown to have minimal toxic side effects compared to systemic chemotherapy."

"This trial is also significant because our center is the only one nationwide that is offering this experimental therapy to treat pleural mesothelioma," added Dr. Taub. "We are very focused on offering these patients the best treatment that medical technology can offer while simultaneously working to preserve quality of life."

Researchers also anticipate that the radiation therapy will kill the cancer cells on surface of the lung while sparing other parts of the lung and surrounding vital tissues.

"Delivery of radiation therapy directly into the pleural cavity is a strategy that has been employed since 1945. Today, direct injection of radioactive isotope P-32 may prove to be a significant and effective therapeutic approach for selected mesothelioma patients," adds Dr. Rashid Fawwaz, study co-investigator, radiologist at NewYork-Presbyterian/Columbia and professor of clinical radiology at Columbia University College of Physicians and Surgeons.

"Overall, it is hoped that this study will decrease the need for patients to undergo radical surgery," states Dr. Joshua Sonett, study co-investigator, chief of general thoracic surgery, surgical director of the Lung Transplant Program and surgical director of the High-Risk Lung Assessment Program at NewYork-Presbyterian/Columbia and professor of clinical surgery at Columbia University College of Physicians and Surgeons.

Participating patients will receive several rounds of targeted chemotherapy using the drugs cisplatin and doxorubicin via surgically implanted catheters. Some patients will be randomly selected to receive additional systemic (intravenous) chemotherapy using the drugs cisplatin and pemetrexed. All patients will receive targeted radiotherapy using the P-32 radioisotope. Patients may elect to receive additional surgical treatment, including removal of the affected lung lining or lung. Subsequently, patients will be offered outpatient systemic chemotherapy with cisplatin and pemetrexed.

The investigators previously led a prospective study that employed a similar protocol for patients with pleural mesothelioma as well as those with the more retractable sarcomatous disease. Completed in 2002, the study reported a median survival of 70 months, and a three-year survival of 67 percent (American Journal of Clinical Oncology, February 2008).

Source: New York- Presbyterian Hospital/Columbia University Medical Center

Frog molecule could provide drug treatment for brain tumors
A synthetic version of a molecule found in the egg cells of the Northern Leopard frog (Rana pipiens) could provide the world with the first drug treatment for brain tumours.
Talcum powder stunts growth of lung tumors
Talcum powder has been used for generations to soothe babies’ diaper rash and freshen women’s faces. But University of Florida researchers report the household product has an additional healing power: The ability to stunt cancer growth by cutting the flow of blood to metastatic lung tumors.
Blood 'fingerprints' for cancer
Serum microRNAs (miRNAs) can serve as biomarkers for the detection of diseases including cancer and diabetes, according to research published online this week in Cell Research. The findings pave the way for a revolutionary non-invasive diagnostic tool.
Suicide risks studied in drugs for physical ills
(AP) -- Cody Miller was a high school football player who was allergic to ragweed. Douglas Briggs was a doctor coping with pain from an old back injury. Both are now dead, hanging victims driven to suicide, their families believe, when drugs prescribed to relieve physical symptoms upset their mental and emotional balance. Federal drug regulators are investigating to see if the families could be right.
World first: Lasers used in keyhole surgery for brain cancer
In a ground-breaking advance, French neurosurgeons on Friday said they had successfully treated brain tumours through ultra-keyhole surgery, using a tiny fibre-optic laser to destroy cancerous cells.
Heavy breathing -- an obscure link in asthma and obesity
There is a strong link between obesity and asthma and as the prevalence of both conditions has been increasing steadily, epidemiologists have speculated that there is an underlying condition that connects the two. But one long-suspected link, the systemic inflammation associated with obesity, has been ruled out by a recent New Zealand study that found no evidence of its involvement.
Research examines variations of rare lung disease
Lymphangioleiomyomatosis, or LAM, is a rare but serious lung disease that may cause severe respiratory symptoms in patients. The often-fatal disease has no cure.
OU researchers developing new tool to detect cancer
Early cancer detection can significantly improve survival rates. Current diagnostic tests often fail to detect cancer in the earliest stages and at the same time expose a patient to the harmful effects of radiation. Led by Dr. Patrick McCann, a small group of internationally known researchers at the University of Oklahoma with expertise in the development of mid-infrared lasers is working to create a sensor to detect biomarker gases exhaled in the breath of a person with cancer.

New clinical trial for patients with asbestos-associated lung cancer

Related stories:

News discussion: